At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed invasive breast cancer, stages II-III per AJCC 6th edition
- ✓Completion of preoperative (neoadjuvant) chemotherapy with a standard regimen
- ✓Completion of definitive resection of primary tumor with adequate excision of gross disease
- ✓Presence of significant residual invasive disease on pathologic review following preoperative chemotherapy
- ✕Metastatic disease
- ✕Known HIV infection
- ✕Pregnancy, planned pregnancy, or breastfeeding
- ✕Uncontrolled intercurrent illness
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Anti-Angiogenesis Treatment After Preoperative Chemotherapy: A Pilot Study in Women With Operable Breast Cancer
In Brief
A clinical study evaluating Bevacizumab, Cyclophosphamide, and 2 other interventions for Breast Cancer. Completed, enrolled 164 participants across 5 sites.
Detailed Summary
The purpose of this research study is to study the effects (good and bad) of bevacizumab alone, bevacizumab with low-dose continuous chemotherapy (called metronomic chemotherapy), or bevacizumab with capecitabine, on you and your cancer. The goals of the study will be to: * Examine the safety of these drugs * See how easy or difficult it is to be treated with them * Monitor for any signs of recurrent cancer * Look at blood markers that might indicate how the treatment is working
Study Details
Timeline
Interventions
Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months
Once a day for 6 months
Twice daily for the first two days of every week for 6 months
Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycles (18 weeks) Bevacizumab: 15 mg/kg IV day 1 every 3 weeks x 1 year (17 cycles)